Fieldview Capital Management’s United Therapeutics UTHR Stock Holding History

Fieldview Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-674	Closed	-$400K	–	722
2026 Q1	$400K	Sell	674 -407	-38%	-$203K	0.12%	311
2025 Q4	$527K	Buy	+1,081	New	+$503K	0.09%	266
2025 Q2	–	Sell	-1,394	Closed	-$430K	–	525
2025 Q1	$430K	Buy	+1,394	New	+$478K	0.06%	298

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Fieldview Capital Management's UTHR Position: Q2 2026 in Review

Fieldview Capital Management sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 674 shares — an estimated $400K sold.

Fieldview Capital Management first reported a position in UTHR in Q1 2025 and held it in 3 quarters. The position peaked at $527K in Q4 2025. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Fieldview Capital Management reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Fieldview Capital Management sold 674 United Therapeutics shares in Q2 2026, an estimated $400K.
Fieldview Capital Management first reported a position in United Therapeutics in Q1 2025 and held it in 3 quarters.
Fieldview Capital Management's United Therapeutics position peaked at $527K in Q4 2025.
874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.